Toothpaste Market Segments: Price Is Inversely Related to Clinical Claims

Surveying roughly 28 toothpastes from about $1 to $75 reveals an inverse relationship between price and clinical claims. The market splits into four loose segments, and only one of them is really competing on dental outcomes. **Luxury** brands (imported Japanese tubes, Aesop-style apothecary lines, prices up to $75) sell on sensory experience — taste, scent, packaging — with copy like 'pleasure of taste, sweet floral mint.' Health benefits are rarely mentioned because that is not the purchase trigger. **Alternative** or 'crunchy' brands sell on absence: no fluoride, vegan, no SLS, no synthetic dyes. The marketing is structured around what is *not* in the tube rather than what it does. **Cosmetic mid-range** brands (most drugstore whitening and 'fresh breath' lines) sell on aesthetic outcomes — whitening, breath freshness, and what one reviewer called 'creative synonyms for mint.' Active ingredients are present but secondary to the cosmetic promise. **Therapeutic** brands (Crest, Colgate, Sensodyne, and similar cheap mainstream tubes) are the only segment making concrete clinical claims — cavity prevention, sensitivity reduction, gum health — backed by sciency diagrams and the ADA Seal of Acceptance. The practical implication: when the goal is dental health, the cheap therapeutic tube is usually the rational pick. A $1 Colgate Triple Action is doing roughly the same therapeutic work as anything 50× the price, and is often doing more of it than the $75 luxury option. Premium pricing in this category is mostly buying experience, story, or absence — not better teeth. See also Online Glasses Are 80-95% Cheaper Than Opticians: The Luxottica Monopoly Markup for a related pattern of brand-driven markup with little functional benefit.